As industry leaders and sales executives, it's imperative to stay informed of these advancements, comprehend their implications, and harness their capabilities to enhance patient care
13 Fourteen states cover GLP-1s for obesity under Medicaid
Oral GLP-1 formulations like danuglipron were designed to offer convenience over injections, but development challenges including gastrointestinal side effects have prevented their approval
Research protocols for bone healing applications have typically used dosages in the range of 200 to 300 micrograms administered subcutaneously, though the specific BPC-157 dosing protocols vary depending on the study design and objectives
The development of tirzepatide and ongoing investigation of GLP-1-based multi-agonists has opened up an exciting new chapter in GLP-1 pharmacology [173], with an expanding range of molecules producing impressive results in early clinical trials
Reduced stress, anxiety, and improved sleep quality
